Cabaletta Bio Long Term Debt 2019-2025 | CABA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cabaletta Bio long term debt from 2019 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cabaletta Bio long term debt from 2019 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$214.8B
Amgen (AMGN)	$160.4B
Gilead Sciences (GILD)	$135.3B
Vertex Pharmaceuticals (VRTX)	$119B
Bristol Myers Squibb (BMY)	$97.8B
CSL (CSLLY)	$78.3B
GSK (GSK)	$74.7B
Regeneron Pharmaceuticals (REGN)	$59.4B
Alnylam Pharmaceuticals (ALNY)	$42.3B
Argenex SE (ARGX)	$35B
BioNTech SE (BNTX)	$26.7B
Royalty Pharma (RPRX)	$19.9B
Insmed (INSM)	$19.8B
Biogen (BIIB)	$18.9B
Illumina (ILMN)	$15.5B
Genmab (GNMSF)	$14.5B
Genmab (GMAB)	$14.1B
Incyte (INCY)	$13.3B
Moderna (MRNA)	$12.5B
Exelixis (EXEL)	$12.2B
BioMarin Pharmaceutical (BMRN)	$11.2B
Ascendis Pharma (ASND)	$10.8B
QIAGEN (QGEN)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Exact Sciences (EXAS)	$9.8B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Bio-Techne Corp (TECH)	$8.4B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$7.9B
Legend Biotech (LEGN)	$7.7B